Journal:Protein Science:2

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (10:34, 12 December 2024) (edit) (undo)
 
Line 4: Line 4:
<hr/>
<hr/>
<b>Molecular Tour</b><br>
<b>Molecular Tour</b><br>
-
Crystal structure of ''Tc''AChE <scene name='72/725874/Cv/27'>shows its two subdomains</scene> (<font color='purple'><b>residues 4-305, purple</b></font>, and <font color='red'><b>residues 306-535, red</b></font>). The <scene name='72/725874/Cv/29'>entrance to the active-site gorge</scene> located between the two sub-domains. There are several of the conserved aromatic residues: <scene name='72/725874/Cv/30'>Trp279</scene>, in the peripheral anionic site (PAS) at the top of the gorge; <scene name='72/725874/Cv/31'>Tyr121</scene>, mid-way down the gorge, and <scene name='72/725874/Cv/32'>Trp84</scene>, the principal element of the catalytic ‘anionic’ sub-site (CAS), near the bottom. CAS involves the <scene name='72/725874/Cv/33'>catalytic triad Ser200, His440, and Glu327</scene>. <span style="color:yellow;background-color:black;font-weight:bold;">The carbon atoms of these conserved residues colored yellow</span>.
+
Crystal structure of ''Tc''AChE <scene name='72/725874/Cv/40'>shows its two subdomains</scene> (<font color='purple'><b>residues 4-305, purple</b></font>, and <font color='red'><b>residues 306-535, red</b></font>). The <scene name='72/725874/Cv/29'>entrance to the active-site gorge</scene> located between the two sub-domains. There are several of the conserved aromatic residues: <scene name='72/725874/Cv/30'>Trp279</scene>, in the peripheral anionic site (PAS) at the top of the gorge; <scene name='72/725874/Cv/31'>Tyr121</scene>, mid-way down the gorge, and <scene name='72/725874/Cv/32'>Trp84</scene>, the principal element of the catalytic ‘anionic’ sub-site (CAS), near the bottom. CAS involves the <scene name='72/725874/Cv/33'>catalytic triad Ser200, His440, and Glu327</scene>. <span style="color:yellow;background-color:black;font-weight:bold;">The carbon atoms of these conserved residues colored yellow</span>.
Structure-based drug design utilizes experimental 3D apo-protein or complex structures that are usually retrieved from the PDB. Over 57% of the crystallographic PDB entries were obtained with polyethyleneglycols (PEGs) as precipitant and/or as cryoprotectant, but fewer than 6% of
Structure-based drug design utilizes experimental 3D apo-protein or complex structures that are usually retrieved from the PDB. Over 57% of the crystallographic PDB entries were obtained with polyethyleneglycols (PEGs) as precipitant and/or as cryoprotectant, but fewer than 6% of

Current revision

Drag the structure with the mouse to rotate
  1. Dym O, Song W, Felder C, Roth E, Shnyrov V, Ashani Y, Xu Y, Joosten RP, Weiner L, Sussman JL, Silman I. The Impact of Crystallization Conditions on Structure-Based Drug Design: A Case Study on the Methylene Blue/Acetylcholinesterase Complex. Protein Sci. 2016 Mar 14. doi: 10.1002/pro.2923. PMID:26990888 doi:http://dx.doi.org/10.1002/pro.2923

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Joel L. Sussman, Jaime Prilusky

This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.
Personal tools